- Open
- 9.00
- High
- 9.50
- Low
- 8.50
- Close
- 8.75
- Change
- -0.50 (-5.56%)
- Volume
- 88,411
| 15 Oct 2026 | 07:00:07 | Issue of Equity |
| 2 Oct 2026 | 07:00:03 | Notice of AGM |
| 21 Sept 2026 | 07:00:07 | Interim Results |
| 17 Sept 2026 | 07:00:04 | Appointment of Non-executive Chair |
| 20 Aug 2026 |
AMC is a mineral exploration company that specializes in nickel copper sulphide and operates in the far east of Russia. The company's main focus is on the Kun-Manie sulphide nickel, copper project situated in Amur Oblast.
| 15 Oct 2026 | 07:00:07 | Issue of Equity |
| 2 Oct 2026 | 07:00:03 | Notice of AGM |
| 21 Sept 2026 | 07:00:07 | Interim Results |
| 17 Sept 2026 | 07:00:04 | Appointment of Non-executive Chair |
| 20 Aug 2026 |
AMC is a mineral exploration company that specializes in nickel copper sulphide and operates in the far east of Russia. The company's main focus is on the Kun-Manie sulphide nickel, copper project situated in Amur Oblast.
| 11:05:21 |
| Commencement of Patient Recruitment |
| 21 Apr 2026 |
| AIM movers: Intercede contract upsell and upgrade for Gear4Music |
| 25 Mar 2026 | AIM movers: Volex beats estimates and Seascape Energy Asia cash call |
| 17 Mar 2026 | AIM movers: ImmuPharma cash raising and CRISM Therapeutics orphan designation |
| 11:05:21 |
| Commencement of Patient Recruitment |
| 21 Apr 2026 |
| AIM movers: Intercede contract upsell and upgrade for Gear4Music |
| 25 Mar 2026 | AIM movers: Volex beats estimates and Seascape Energy Asia cash call |
| 17 Mar 2026 | AIM movers: ImmuPharma cash raising and CRISM Therapeutics orphan designation |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +0.0% | |
| £11m | +0.0% | |
| £11m | -0.2% | |
| £9m | -0.7% | |
CRTXCrism Therapeutics Corporation | £7m | -0.2% |
| £2m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +0.0% | |
| £11m | +0.0% | |
| £11m | -0.2% | |
| £9m | -0.7% | |
CRTXCrism Therapeutics Corporation | £7m | -0.2% |
| £2m | -0.7% |
